

GLAXOSMITHKLINE PLC
Form 6-K
July 20, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 20 July 2016

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

GlaxoSmithKline plc (the 'Company')
Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Dr S Dexter
 PCA of
- b) Position/status Dr P J T Vallance
 (President, Pharmaceuticals
 R&D)
- c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of Ordinary shares of 25 pence
 The financial each ('Ordinary Shares')
- a) instrument ISIN: GB0009252882

- b) Nature of Acquisition of Ordinary
 The transaction Shares following the
 re-investment of dividends
 paid to shareholders on 14
 July 2016.

- c) Price(s) and Price(s) Volume(s)
 volume(s) £16.56 351
 n/a (single transaction)

- d) Aggregated
 information
 Aggregated volume
 Price

- e) Date of the 2016-07-18
 transaction

- f) Place of London Stock Exchange
 the transaction (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)
Date: July 20, 2016

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc